CMBA
ANIP icon

C.M. Bidwell & Associates’s ANI Pharmaceuticals ANIP Stock Holding History

C.M. Bidwell & Associates’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.8K Hold
916
– – 0.03% 201
2026
Q1 		$70.4K Sell
916
-290
-24% -$22.6K 0.03% 194
2025
Q4 		$95.2K Buy
1,206
+7
+0.6% +$606 0.05% 183
2025
Q3 		$110K Hold
1,199
– – 0.05% 173
2025
Q2 		$78.2K Hold
1,199
– – 0.04% 189
2025
Q1 		$80.3K Sell
1,199
-25
-2% -$1.49K 0.05% 174
2024
Q4 		$67.7K Hold
1,224
– – 0.04% 211
2024
Q3 		$73K Buy
1,224
+39
+3% +$2.38K 0.04% 204
2024
Q2 		$75.5K Hold
1,185
– – 0.05% 203
2024
Q1 		$81.9K Hold
1,185
– – 0.06% 199
2023
Q4 		$65.3K Sell
1,185
-2,081
-64% -$115K 0.05% 203
2023
Q3 		$190K Buy
3,266
+2,611
+399% +$151K 0.14% 121
2023
Q2 		$35.3K Buy
+655
New +$29K 0.03% 320

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

C.M. Bidwell & Associates's ANIP Position: Q2 2026 in Review

C.M. Bidwell & Associates held its ANI Pharmaceuticals (ANIP) position steady in Q2 2026 at 916 shares worth $75.8K. The position accounts for 0.03% of the portfolio, ranked #201.

C.M. Bidwell & Associates first reported a position in ANIP in Q2 2023 and has held it in 13 quarters since. The position peaked at $190K in Q3 2023. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • C.M. Bidwell & Associates held 916 shares of ANI Pharmaceuticals worth $75.8K as of Q2 2026.
  • C.M. Bidwell & Associates left its ANI Pharmaceuticals share count unchanged in Q2 2026.
  • ANI Pharmaceuticals made up 0.03% of C.M. Bidwell & Associates's portfolio in Q2 2026, its #201 holding.
  • C.M. Bidwell & Associates first reported a position in ANI Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • C.M. Bidwell & Associates's ANI Pharmaceuticals position peaked at $190K in Q3 2023.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.